State of the Nation

Discussion in 'Galderma' started by anonymous, May 14, 2020 at 11:57 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Flemming & Thomas:

    Don’t understand our business

    Have destroyed company culture

    Add zero value

    Haven’t accomplished anything in 6 months

    Are incapable of handling a crisis

    Spend but don’t drive revenue

    Don’t lead

    Need McKinsey to do their job

    Dream of big pharma/ rare disease

    Don’t communicate with anyone

    Couldn’t sell a single Restylane

    Have zero accountability

    Are the most despicable leaders

    Collect hugely unjustified salaries

    Will never lift a little finger for you

    Are only in it for the money
     

  2. anonymous

    anonymous Guest

    It's the worst I've ever seen. So many have checked out. It is very hard to get anything done because no one has a vested interest anymore. No communication or leadership. Unnecessary reorganization. Terrible HR. Constant cost cutting. Sexist culture. Need I say more....
     
  3. anonymous

    anonymous Guest

    Are all our investors wearing blindfolds???
     
  4. anonymous

    anonymous Guest

    Absolutely a fair assessment above, every point is accurate.
     
  5. anonymous

    anonymous Guest

    ✔️✔️✔️✔️✔️✔️✔️✔️✔️✔️✔️✔️✔️✔️

    Yes! you checked just about all the boxes with that list.
     
  6. anonymous

    anonymous Guest

    Not throwing shade on anyone still here, but objectively and factually, the first to leave during any exodus are the most talented. They leave because they're valued elsewhere and because they can.

    What an organization is then left with is the relatively lower performers. This is the case with all of Galderma .

    Flemming will soon be left with the 'B Team' and looking for another company to fck up himself. Actually, he's screwed either way.

    This is clearly the quickest and deepest collapse of an organization that's happened, made worse by the upcoming restructuring.
     
  7. anonymous

    anonymous Guest

    Speaking of reputation ...
    I was talking with a recruiter today and without diming them out, I couldn't believe how much detail they knew about the situation here.
    None of it was positive, but the amount of inside knowledge was surprising. Word is out!
     
  8. anonymous

    anonymous Guest

    To all the naive, ignorant ass kissers
    Anyone working here could get the axe at anytime. We are all vulnerable. We are in quicksand.
    Galderma will soon be dissolved. Ax and Cx are over! Rx is the future!
     
  9. anonymous

    anonymous Guest

    Rx is the future? That is the dumbest post ever!
    The future if you have a robust pipeline and good products. Telemedicine will change medicine as we know it! Acne and Rosacea new and follow up visits, are tailor made for Telemedicine. Unless we acquire a biologic or we bring Nemo to market quickly are toast!
     
  10. anonymous

    anonymous Guest

    Nemo data looks very week and by the time it comes to the market the market place will be so crowded with so many biologic products it will have a very difficult time getting any real share. Galderma's best days are so far behind her it is not funny anymore. I would get out if you can.
     
  11. anonymous

    anonymous Guest

    You are right.
    Med Derm is dead. Not only for Galderma but for everyone. Nemo is the best drug in our pipeline BUT will launch (IF we ever launch) 2-3 years too late and with handcuffs!!
     
  12. anonymous

    anonymous Guest

    Galderma will be 4th to market. It won’t be easy
     
  13. anonymous

    anonymous Guest

    Consumer BU will be sold later next year to pay back the loan, EQT got from banks. Then Ax and Rx in 2023. Forget about the commercialization of Nemo...
     
  14. anonymous

    anonymous Guest

    This is an accurate prediction. Consumer will be sold first. Anything else is wishful thinking by the ignorant and irrational.
     
  15. anonymous

    anonymous Guest

    Amen. Let's not kid ourselves, topical derm companies are dead.
     
  16. anonymous

    anonymous Guest

    I think the HBR article is already being written:

    (1) Layoff loyal & trustworthy employees
    (2) Replace with Rare Disease cronies
    (2) Outsource everything to McKinsey
    (3) Destroy culture & trust
    (4) Grab a huge wad of cash for themselves
     
  17. anonymous

    anonymous Guest

    Clinical trial suspensions rocket in the wake of COVID-19. Nemo will be delayed.
     
  18. anonymous

    anonymous Guest

    Does anyone have a clue what our company strategy is? Where is this company going and why don't we have any leadership??? Seems like we are a $3bn Titanic adrift at sea waiting to hit an iceberg.
     
  19. anonymous

    anonymous Guest

    Upper management chooses not to be transparent because it's not very inspiring and most of us would look for other jobs knowing there is no objective other than making as much personal dollars as fast as possible. Sad but true.
     
  20. anonymous

    anonymous Guest

    Does EB know we are launching a brand?
    Complete silence from headquarters on Kysse.